文献速递慢性肾脏病

通过g公式分析在EQUAL研究中评估CKD-MBD生物标志物改变对CKD进展的因果影响

Causal assessment of CKD-MBD biomarker alterations on CKD progression through a g-formula analysis in the EQUAL study.
PubMed 文献 · Kidney Int · 2025-09-09

该研究基于EQUAL研究1709例65岁以上晚期非透析CKD患者,使用g公式分析纵向血磷、甲状旁腺激素和钙对eGFR下降、透析启动及死亡或透析复合风险的影响。孤立性高磷血症和甲状旁腺功能亢进与CKD进展风险升高相关,而孤立性高钙血症无关;高磷血症、低钙血症和甲状旁腺功能亢进组合表型最差。

要点

  • 孤立性高磷血症和甲状旁腺功能亢进与CKD进展风险升高相关,孤立性高钙血症无关。
  • 高磷血症合并低钙血症和甲状旁腺功能亢进组合表型最差,3年eGFR平均差异为-3.71 ml/min。
  • 该组合表型启动透析风险高75%(HR 1.75,95%CI 1.35-2.10),大部分风险归因于高磷血症。

核心结论

  • 在晚期非透析老年CKD患者中,高磷血症尤其合并低钙血症和甲状旁腺功能亢进时,导致CKD进展风险增加。

研究设计与样本

  • 研究使用EQUAL研究数据,纳入来自六个欧洲国家的1709例65岁及以上、eGFR≤20 ml/min/1.73 m²的晚期非透析CKD患者。
  • 采用g公式进行因果推断,以避免信息性删失、竞争风险和时间依赖混杂偏倚。

主要发现

  • 孤立性高磷血症和甲状旁腺功能亢进与CKD进展风险升高相关,孤立性高钙血症无关。
  • 高磷血症合并甲状旁腺功能亢进、低钙血症合并甲状旁腺功能亢进均与显著升高风险相关。
  • 高磷血症、低钙血症和甲状旁腺功能亢进组合表型最差,3年eGFR平均差异为-3.71 ml/min(95%CI:-5.44,-2.15),启动透析风险高75%(HR 1.75,95%CI 1.35-2.10)。
  • 大部分风险归因于高磷血症。
  • 异常矿物生物标志物对eGFR下降的影响在两性间相似,但启动透析相关风险在男性中似乎更强。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) may be both a cause and a consequence of CKD progression. Here, we examine the individual and joint effect of longitudinal circulating phosphate, parathyroid hormone, and calcium levels on estimated glomerular filtration rate (eGFR) decline, the risk of starting dialysis and the composite risk of death or dialysis, in a cohort of elderly patients with advanced CKD not on dialysis. Secondly, we explore whether these effects differ between men and women. METHODS: We used data from 1709 participants in the European Quality study, which includes patients aged 65 and older with eGFR 20 ml/min per 1.73 m2 or less from six European countries. To avoid bias due to informative censoring, competing risks and time-varying confounding, we used the g-formula for causal inference. RESULTS: Isolated hyperphosphatemia and hyperparathyroidism were associated with a higher risk of CKD progression, whereas isolated hypercalcemia was not. The combination of hyperphosphatemia with hyperparathyroidism, and of hypocalcemia with hyperparathyroidism were also associated with significantly higher risk. The most adverse phenotype was the combination of hyperphosphatemia, hypocalcemia and hyperparathyroidism, which led to a mean difference in eGFR after three years of -3.71 ml/min (95% confidence intervals: -5.44, -2.15) and a 75% higher risk of starting dialysis (hazard ratio 1.75, 95% confidence interval 1.35-2.10), compared to having all biomarkers in their reference ranges. Most of this risk was attributable to hyperphosphatemia. Although the effect of abnormal mineral biomarkers on eGFR decline was similar between sexes, the associated risk of starting dialysis seemed stronger in men than in women. CONCLUSIONS: Among older men and women with advanced CKD not receiving dialysis, the presence of hyperphosphatemia, especially when combined with hypocalcemia and hyperparathyroidism, leads to an increased risk of CKD progression.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Magagnoli L, Cozzolino M, Caskey FJ, et al. Causal assessment of CKD-MBD biomarker alterations on CKD progression through a g-formula analysis in the EQUAL study. Kidney Int. 2025. PMID: 40935133. doi:10.1016/j.kint.2025.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。